Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
PHASE3
The study evaluated the efficacy and safety of letermovir (MK-8228) for the...
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
PHASE2
This was an open-label, controlled study, conducted at US sites to evaluate...
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
PHASE3
This study aims to evaluate the safety, efficacy and pharmacokinetics (PK) ...
Status
Completed
Location
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital ( Site 0002)